Tiwaskar Mangesh, Deb Prasun, Khadgawat Rajesh, Sreenivasamurthy L, Deka Nilakshi, Karthik B, Karuppan Ashwin, Bhattacharjee Dipanjan, Mohan Viswanathan
Senior Consultant, Shilpa Medical Research Center, Mumbai, Maharashtra.
Head, Department of Endocrinology, KIMS Hospital, Hyderabad, Telangana.
J Assoc Physicians India. 2020 Dec;68(12[Special]):9-12.
Prior to the discovery of insulins, diabetes was managed predominantly by dietary interventions. Discovery of insulin and its first human trial highlighted the need for higher purity insulin thereby steering the subsequent journey of insulin development. Considering the limitations of the early preparations like short duration of action and need for several injections per day, attempts at protracting the duration of insulin action were made. This led to the development of intermediate-acting Neutral Protamine Hagedorn (NPH) and the Lente family of insulins. This review provides insights into the discovery of insulins and the shortcomings of early protracted release preparations, which in turn, gave impetus to the search for a 'true' basal insulin, which could mimic the endogenous human basal insulin secretion.
在胰岛素被发现之前,糖尿病主要通过饮食干预来控制。胰岛素的发现及其首次人体试验凸显了对更高纯度胰岛素的需求,从而引领了随后胰岛素的研发历程。考虑到早期制剂存在作用时间短以及每天需要多次注射等局限性,人们尝试延长胰岛素的作用时间。这导致了中效中性鱼精蛋白锌胰岛素(NPH)和赖脯胰岛素家族的研发。本综述深入探讨了胰岛素的发现以及早期长效释放制剂的缺点,这些缺点反过来推动了对一种能够模拟内源性人体基础胰岛素分泌的“真正”基础胰岛素的探索。